These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18511780)

  • 1. Merck to pay $58m in settlement over rofecoxib advertising.
    Charatan F
    BMJ; 2008 May; 336(7655):1208-9. PubMed ID: 18511780
    [No Abstract]   [Full Text] [Related]  

  • 2. Merck to pay $5bn in rofecoxib claims.
    Charatan F
    BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982
    [No Abstract]   [Full Text] [Related]  

  • 3. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ
    N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract]   [Full Text] [Related]  

  • 4. Merck faces ongoing claims after Texan ruling on rofecoxib.
    Tanne JH
    BMJ; 2005 Sep; 331(7515):471. PubMed ID: 16141139
    [No Abstract]   [Full Text] [Related]  

  • 5. Merck pays $1bn penalty in relation to promotion of rofecoxib.
    Tanne JH
    BMJ; 2011 Nov; 343():d7702. PubMed ID: 22123916
    [No Abstract]   [Full Text] [Related]  

  • 6. 94% of patients suing Merck over rofecoxib agree to company's offer.
    Charatan F
    BMJ; 2008 Mar; 336(7644):580-1. PubMed ID: 18340064
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent developments in health law. Merck and the Vioxx decision: playing by the changing rules of the chemical exposure game.
    Cohen JG
    J Law Med Ethics; 2005; 33(4):866-9. PubMed ID: 16686256
    [No Abstract]   [Full Text] [Related]  

  • 8. Will Merck survive Vioxx?
    Simons J; Stipp D
    Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
    [No Abstract]   [Full Text] [Related]  

  • 9. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.
    Ross JS; Hill KP; Egilman DS; Krumholz HM
    JAMA; 2008 Apr; 299(15):1800-12. PubMed ID: 18413874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preacher who's raising hell with Merck.
    Parloff R
    Fortune; 2005 Aug; 152(3):20. PubMed ID: 16097189
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA warns Merck over its promotion of rofecoxib.
    Josefson D
    BMJ; 2001 Oct; 323(7316):767. PubMed ID: 11588068
    [No Abstract]   [Full Text] [Related]  

  • 12. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug firms back-pedal on direct advertising.
    Nature; 2005 Aug; 436(7053):910-1. PubMed ID: 16107811
    [No Abstract]   [Full Text] [Related]  

  • 14. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 15. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 16. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 17. Reforming direct-to-consumer advertising.
    Liang BA; Mackey T
    Nat Biotechnol; 2011 May; 29(5):397-400. PubMed ID: 21552236
    [No Abstract]   [Full Text] [Related]  

  • 18. Merck defends Vioxx in court, as publisher apologises for fake journal.
    Moynihan R
    BMJ; 2009 May; 338():b1914. PubMed ID: 19433504
    [No Abstract]   [Full Text] [Related]  

  • 19. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.
    Psaty BM; Kronmal RA
    JAMA; 2008 Apr; 299(15):1813-7. PubMed ID: 18413875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEJM editor gives pretrial evidence in Vioxx case.
    Tanne JH
    BMJ; 2006 Feb; 332(7536):255. PubMed ID: 16455704
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.